CBER Counterfeit Procedures Stress Need For Improved Communication
The Center for Biologics Evaluation & Research's standard procedures for responding to a counterfeit product event emphasizes the need for more efficient communication between FDA and outside parties
You may also be interested in...
FDA's anticounterfeiting strategy advocates radio frequency identification in lieu of paper pedigrees to secure the drug supply chain
Johnson & Johnson's Ortho Biotech division appears to have a recurring problem with counterfeiting of Procrit in Florida
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011